SCHEDULE: Frazier Life Sciences Funds Disclose Lexeo Stake
Beneficial Ownership Report
Frazier Life Sciences and affiliated funds have filed an amended Schedule 13G, disclosing their beneficial ownership in Lexeo Therapeutics, Inc. common stock.
Summary
- Frazier Life Sciences Public Fund, L.P. (FLSPF) and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 3,073,467 shares of Lexeo Therapeutics, Inc. common stock, representing 5.7% of the class.
- Frazier Life Sciences Public Overage Fund, L.P. (FLSPOF) and its related entities (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 624,804 shares, representing 1.2% of the class.
- Frazier Life Sciences X, L.P. (FLS X) and its related entities (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 87,424 shares, representing 0.2% of the class.
- Frazier Life Sciences XI, L.P. (FLS XI) and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 232,784 shares, representing 0.4% of the class.
- Frazier Life Sciences XII, L.P. (FLS XII) and its related entities (FHMLS XII, L.P. and FHMLS XII, L.L.C.) collectively beneficially own 406,246 shares, representing 0.8% of the class.
- The beneficial ownership percentages are calculated based on 33,196,997 shares outstanding as of May 12, 2025, plus 20,790,120 shares sold in a public offering, totaling 53,987,117 shares.
- The reporting persons also hold warrants to acquire additional shares, which are not included in the reported beneficial ownership due to beneficial ownership limitations (typically 9.99%).
- Specific warrant holdings include: FLSPF with 2,647,440 warrants, FLSPOF with 781,005 warrants, FLS X with 109,280 warrants, FLS XI with 290,980 warrants, and FLS XII with 507,809 warrants.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by institutional investors, common in the biotechnology and pharmaceutical sectors where venture capital and life sciences funds often hold significant stakes in publicly traded companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership and potential influence on corporate governance, although the filing states the securities were not acquired for the purpose of changing or influencing control.
Key Dates
| Date | Description |
|---|---|
| 2017-07-31 | Date of Power of Attorney filing for James N. Topper and Patrick J. Heron. |
| 2021-08-16 | Date of Power of Attorney filing for Albert Cha and James Brush. |
| 2022-04-18 | Date of Power of Attorney filing for Daniel Estes. |
| 2025-05-12 | Date of Issuer's Common Stock outstanding count (33,196,997 shares) as reported in Form 10-Q/A. |
| 2025-05-15 | Date of Issuer's Quarterly Report on Form 10-Q/A filing. |
| 2025-05-27 | Date of Issuer's Current Report on Form 8-K filing regarding public offering. |
| 2025-06-04 | Date of Joint Filing Agreement (Exhibit 99.1). |
| 2025-06-30 | Date of event requiring the filing of this Schedule 13G statement. |
| 2025-08-14 | Date of signing and filing of this Schedule 13G Amendment No. 1. |
Keywords
Lexeo Therapeutics, Frazier Life Sciences, Beneficial Ownership, Schedule 13G, Common Stock, Investment Fund, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.